GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding
Overview
Affiliations
GDF-8 is a new member of the TGF-beta superfamily which appears to be a negative regulator of skeletal muscle mass. Factors which regulate the biological activity of GDF-8 have not yet been identified. However, the biological activities of TGF-beta superfamily members, TGF-beta1, -beta2 and -beta3, can be inhibited by noncovalent association with TGF-beta1, -beta2 and beta3 propeptides cleaved from the amino-termini of the TGF-beta precursor proteins. In contrast, the propeptides of other TGF-beta superfamily members do not appear to be inhibitory. In this investigation, we demonstrate that purified recombinant GDF-8 propeptide associates with purified recombinant GDF-8 to form a noncovalent complex, as evidenced by size exclusion chromatography and chemical crosslinking analysis. Furthermore, we show that GDF-8 propeptide inhibits the biological activity of GDF-8 assayed on A204 rhabdomyosarcoma cells transfected with a (CAGA)12 reporter construct. Finally, we demonstrate that GDF-8 propeptide inhibits specific GDF-8 binding to L6 myoblast cells. Collectively, these data identify the GDF-8 propeptide as an inhibitor of GDF-8 biological activity.
Design of high-affinity binders to immune modulating receptors for cancer immunotherapy.
Yang W, Hicks D, Ghosh A, Schwartze T, Conventry B, Goreshnik I Nat Commun. 2025; 16(1):2001.
PMID: 40011465 PMC: 11865580. DOI: 10.1038/s41467-025-57192-z.
Elashry M, Schneider V, Heimann M, Wenisch S, Arnhold S J Dev Biol. 2025; 13(1).
PMID: 39982358 PMC: 11843916. DOI: 10.3390/jdb13010005.
Wetzlich B, Nyakundi B, Yang J Mol Cell Biochem. 2024; 480(3):1535-1553.
PMID: 39340593 PMC: 11842502. DOI: 10.1007/s11010-024-05120-y.
Dynamic allostery drives autocrine and paracrine TGF-β signaling.
Jin M, Seed R, Cai G, Shing T, Wang L, Ito S Cell. 2024; 187(22):6200-6219.e23.
PMID: 39288764 PMC: 11531391. DOI: 10.1016/j.cell.2024.08.036.
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.
Mackels L, Mariot V, Buscemi L, Servais L, Dumonceaux J Int J Mol Sci. 2024; 25(16).
PMID: 39201450 PMC: 11354404. DOI: 10.3390/ijms25168763.